Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross‐Sectional Study

OBJECTIVE: Clinical trials are regarded as an essential method for developing new treatments and giving patients access to potentially effective medications that are still being studied. This study aimed to evaluate acceptance of participating in clinical trials of new drugs and to further explore the associated factors. METHODS: A population-based cross-sectional study was conducted in China from June 20 to August 31, 2022. We collected demographic data and used visual analog scale scores to assess the public's willingness to accept clinical trials of new drugs (range 0-100). Linear regression analysis was adopted to evaluate the factors related to attitudes toward clinical trials of new drugs. RESULTS: This survey contained 19,710 valid questionnaires to investigate acceptance of participating in clinical trials of new drugs. Participants showed low willingness to accept clinical trials of new drugs, with a mean score of 44.69 out of 100. The results showed that rural residence (β = 3.00), western China (β = 3.15), being married (β = 2.93), older age (31-59 years [β = 3.84], ≥60 years [β = 7.71]), having cancer or rare diseases (β = 5.15), higher monthly household income (>6000 yuan [β = 1.76]), medical-related occupations (β = 8.01), anxiety status (moderate anxiety [β = 1.83]), moderate to severe anxiety [β = 2.66]), perceived stress (β = 0.51), health literacy (β = 0.21), self-efficacy (β = 0.34), and media use (β = 0.42) were associated with higher acceptance of participating in clinical trials of new drugs. However, central China (β = -1.65), female sex (β = -2.29), chronic diseases (β = -2.45), and medical insurance (β = -3.78) were associated with lower acceptance of participating in clinical trials of new drugs. Subgroup analysis demonstrated consistent trends across age and chronic disease subgroups. CONCLUSIONS: This reveales low public willingness to accept clinical trials of new drugs. The willingness is affected by marital status, occupation, area of residence, income, health insurance, physical and mental health status, media use, and health literacy.

Authors

Institutions

Publication Details

Journal
Journal of Evidence-Based Medicine
Published
2026-08-26
DOI
https://doi.org/10.1111/jebm.70176
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross‐Sectional Study

Wai‐Kit Ming, Yuanyuan Zhang, Xiaohan Chen, Shujie Dong et al.
Journal of Evidence-Based Medicine
Ethics in Clinical Research
article

Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross‐Sectional Study

Wai‐Kit Ming, Yuanyuan Zhang, Xiaohan Chen, Shujie Dong, Mengmeng Liu, Yibo Wu, Jinzi Zhang, Qin Han
article en

Abstract

OBJECTIVE: Clinical trials are regarded as an essential method for developing new treatments and giving patients access to potentially effective medications that are still being studied. This study aimed to evaluate acceptance of participating in clinical trials of new drugs and to further explore the associated factors. METHODS: A population-based cross-sectional study was conducted in China from June 20 to August 31, 2022. We collected demographic data and used visual analog scale scores to assess the public's willingness to accept clinical trials of new drugs (range 0-100). Linear regression analysis was adopted to evaluate the factors related to attitudes toward clinical trials of new drugs. RESULTS: This survey contained 19,710 valid questionnaires to investigate acceptance of participating in clinical trials of new drugs. Participants showed low willingness to accept clinical trials of new drugs, with a mean score of 44.69 out of 100. The results showed that rural residence (β = 3.00), western China (β = 3.15), being married (β = 2.93), older age (31-59 years [β = 3.84], ≥60 years [β = 7.71]), having cancer or rare diseases (β = 5.15), higher monthly household income (>6000 yuan [β = 1.76]), medical-related occupations (β = 8.01), anxiety status (moderate anxiety [β = 1.83]), moderate to severe anxiety [β = 2.66]), perceived stress (β = 0.51), health literacy (β = 0.21), self-efficacy (β = 0.34), and media use (β = 0.42) were associated with higher acceptance of participating in clinical trials of new drugs. However, central China (β = -1.65), female sex (β = -2.29), chronic diseases (β = -2.45), and medical insurance (β = -3.78) were associated with lower acceptance of participating in clinical trials of new drugs. Subgroup analysis demonstrated consistent trends across age and chronic disease subgroups. CONCLUSIONS: This reveales low public willingness to accept clinical trials of new drugs. The willingness is affected by marital status, occupation, area of residence, income, health insurance, physical and mental health status, media use, and health literacy.

Journal of Evidence-Based Medicine
Zhejiang International Studies University (CN), Harbin Medical University (CN), City University of Hong Kong (HK), Chinese University of Hong Kong (HK), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Hong Kong Jockey Club (HK), Peking University Third Hospital (CN)
City University of Hong Kong, National Natural Science Foundation of China
Quality Education
Openalex Percentile: Top 8%
Ethics in Clinical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.